Mutual of America Capital Management LLC Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Mutual of America Capital Management LLC decreased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 9.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 16,780 shares of the biopharmaceutical company’s stock after selling 1,664 shares during the period. Mutual of America Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $334,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CPRX. GAMMA Investing LLC raised its stake in shares of Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 681 shares during the period. nVerses Capital LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at about $50,000. CWM LLC lifted its stake in shares of Catalyst Pharmaceuticals by 686.5% during the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the second quarter worth about $70,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at about $173,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.14.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $22.34 on Friday. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 3.26 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a one year low of $13.00 and a one year high of $24.27. The stock has a 50-day simple moving average of $21.21 and a 200 day simple moving average of $18.69.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.